BIOMAT Database Logo BIOMAT Database Logo

[Current Status and Future Perspectives of SCRUM-Japan]. 2017

Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
National Cancer Center Hospital East.

SCRUM-Japan was launched as a nation-wide genome screening consortium for recruiting patients to 35 sponsor-/investigator- initiated registration trials in collaboration with 15 pharmaceutical companies and 240 hospitals. During the first period between February 2015 and March 2017, a total of 4,805 patients have been enrolled. Genomic profiling of each cancer were analyzed and newdrug applications of label expansion are in preparation based on the results of several registration studies including investigator-initiated trial of vandetanib for RET fusion gene positive non-small cell lung cancer. In addition, on-time clinical-genome data sharing with industries and academic institutions and prospective cohort registry for new drug evaluation as a historical control data have already initiated, which will facilitate new agent development in Japan. In the second period started from April 2017, new studies using cutting-edge liquid biopsy and immune-genome panel for precision medi- cine will start soon. These efforts are attempted towards a leading group for innovative clinical/translations researches in the world.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012955 Societies, Medical Societies whose membership is limited to physicians. Medical Societies,Medical Society,Society, Medical
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015894 Genome, Human The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs. Human Genome,Genomes, Human,Human Genomes

Related Publications

Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
Current status and future perspectives of interventional endoscopic ultrasonography in Japan.
April 2019, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
The current status and future perspectives of clinical trial groups in Japan.
October 2013, Breast cancer (Tokyo, Japan),
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
Endoscopic screening for gastric cancer in Japan: Current status and future perspectives.
March 2022, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
[Current status and future perspectives of multimodality treatment for esophageal cancer in Japan].
February 2014, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
[Renovation of medical specialty education system in Japan (current status and future perspectives)].
January 2013, Rinsho shinkeigaku = Clinical neurology,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
Pharmacogenetics: current status and future perspectives.
January 2010, Current pharmaceutical design,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
Immunotherapy: Current Status and Future Perspectives.
April 2019, Digestive diseases and sciences,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
UMIN--current status and future perspectives.
January 2004, Studies in health technology and informatics,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
Nocturia: current status and future perspectives.
October 2011, Current opinion in obstetrics & gynecology,
Atsushi Ohtsu, and Koichi Goto, and Takayuki Yoshino, and Wataru Okamoto, and Katsuya Tsuchihara
Bedaquiline: Current status and future perspectives.
June 2021, Journal of global antimicrobial resistance,
Copied contents to your clipboard!